Enanta Pharmaceuticals (ENTA) Long-Term Deferred Tax (2014 - 2021)

Enanta Pharmaceuticals' Long-Term Deferred Tax history runs 8 years deep, the most recent figure standing at $345000.0 for Q2 2021.

• Quarterly Long-Term Deferred Tax fell 97.74% year-over-year to $345000.0 in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $345000.0 (down 97.74% YoY) and the FY2020 annual result came in at $345000.0, down 96.96% from the prior year.
• Long-Term Deferred Tax was $345000.0 for Q2 2021 at Enanta Pharmaceuticals, roughly flat from $345000.0 in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $17.7 million in Q2 2017 and bottomed at $345000.0 in Q3 2020.
• A 5-year average of $8.5 million and a median of $9.2 million in 2018 frame the typical range for Long-Term Deferred Tax.
• Annual changes were most pronounced in 2017 — Long-Term Deferred Tax jumped 203.32% — and 2021, when it plunged 97.74%.
• Enanta Pharmaceuticals' Long-Term Deferred Tax stood at $7.6 million in 2017, then increased by 22.2% to $9.2 million in 2018, then climbed by 15.22% to $10.7 million in 2019, then tumbled by 96.76% to $345000.0 in 2020, then changed by 0.0% to $345000.0 in 2021.
• Business Quant data shows ENTA's Long-Term Deferred Tax at $345000.0 in Q2 2021, $345000.0 in Q1 2021, and $345000.0 in Q4 2020.